CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

• Status: Not yet recruiting
• Trial end date: 2027-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Carvedilol; Metoprolol

Criteria

Inclusion Criteria:

• Eligible patients are those (including men, women and minorities)

• On hemodialysis

• Received one of the following beta blockers through the VA pharmacy prescribed by a VA provider: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol, nadolol, pindolol, nebivolol

Exclusion Criteria:

• Impaired decision-making capacity

• Patients not receiving carvedilol who have a history of asthma

• known hypersensitivity to any component of either drug

• Provider unwilling to sign a new medication order for a randomized patient

• No surrogate consent will be allowed